Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fluticasone Furoate

FDA-approved product (spray, metered, nasal), marketed as Arnuity Ellipta, Flonase Sensimist Allergy Relief.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Fluticasone Furoate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Airway obstruction
  • Allergic rhinitis
  • Asthma
  • Chronic obstructive pulmonary disease
  • Nasal congestion
  • Rhinitis, Allergic, Perennial
  • Seasonal allergic rhinitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids; Glucocorticoids
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis40.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fluticasone Furoate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fluticasone Furoate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • 12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device

    NCT01623310 · start 2013-09

    Registered record
    Registry ID
    NCT01623310
    Conditions
    Nasal Polyps
    Interventions
    Fluticasone Propionate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-09
    Completion
    2015-10
    Enrolment
    223

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNasal Polyps
    InterventionFluticasone Propionate
    PhasePhase 3
    Registry statusCompleted

  • Individualized Therapy For Asthma in Toddlers

    NCT01606306 · start 2013-02

    Registered record
    Registry ID
    NCT01606306
    Conditions
    Asthma; Wheezing
    Interventions
    daily fluticasone propionate; Montelukast; as-needed fluticasone propionate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-02
    Completion
    2015-04
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma; Wheezing
    Interventiondaily fluticasone propionate; Montelukast; as-needed fluticasone propionate
    PhasePhase 3
    Registry statusCompleted

  • Study FFR116365, an Open-label Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis

    NCT01622231 · start 2012-06

    Registered record
    Registry ID
    NCT01622231
    Conditions
    Rhinitis
    Interventions
    Fluticasone furoate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-06
    Completion
    2012-11
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis
    InterventionFluticasone furoate
    PhasePhase 3
    Registry statusCompleted

  • A 12-Week Study in Adult Subjects With Asthma

    NCT01516086 · start 2012-03

    Registered record
    Registry ID
    NCT01516086
    Conditions
    Asthma
    Interventions
    Fluticasone Propionate (FP)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-03
    Completion
    2013-11
    Enrolment
    498

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionFluticasone Propionate (FP)
    PhasePhase 2
    Registry statusCompleted

  • Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.)

    NCT01555138 · start 2012-02

    Registered record
    Registry ID
    NCT01555138
    Conditions
    Chronic Obstructive Pulmonary Disease
    Interventions
    Indacaterol; Salmeterol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-02
    Completion
    2014-02
    Enrolment
    581

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Obstructive Pulmonary Disease
    InterventionIndacaterol; Salmeterol
    PhasePhase 4
    Registry statusCompleted

  • A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exercise

    NCT01435902 · start 2012-01

    Registered record
    Registry ID
    NCT01435902
    Conditions
    Asthma
    Interventions
    Fluticasone Furoate/Vilanterol Inhalation Powder; Fluticasone Propionate Inhalation Powder
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2012-01
    Completion
    2012-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionFluticasone Furoate/Vilanterol Inhalation Powder; Fluticasone Propionate Inhalation Powder
    PhasePhase 3
    Registry statusWithdrawn

  • Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry

    NCT01498653 · start 2012-01

    Registered record
    Registry ID
    NCT01498653
    Conditions
    Asthma
    Interventions
    GW685698/GW642444; CCI18781
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-01
    Completion
    2013-02
    Enrolment
    313

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionGW685698/GW642444; CCI18781
    PhasePhase 3
    Registry statusCompleted

  • Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study

    NCT01453023 · start 2011-10

    Registered record
    Registry ID
    NCT01453023
    Conditions
    Asthma
    Interventions
    Fluticasone Furoate; Fluticasone Furoate/Vilanterol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-10
    Completion
    2012-06
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionFluticasone Furoate; Fluticasone Furoate/Vilanterol
    PhasePhase 2
    Registry statusCompleted

  • Inhalation of Corticosteroids in Smoking and Non-smoking Asthmatics.

    NCT01400906 · start 2011-07-20

    Registered record
    Registry ID
    NCT01400906
    Conditions
    Asthma
    Interventions
    100 micrograms Fluticasone propionate; 500 micrograms Fluticasone propionate; lactose powder
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-07-20
    Completion
    2012-12-12
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    Intervention100 micrograms Fluticasone propionate; 500 micrograms Fluticasone propionate; lactose powder
    PhasePhase 2
    Registry statusCompleted

  • QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

    NCT01315249 · start 2011-03

    Registered record
    Registry ID
    NCT01315249
    Conditions
    Chronic Obstructive Pulmonary Disease (COPD)
    Interventions
    indacaterol and glycopyrronium (QVA149); Placebo to fluticasone/salmeterol; fluticasone/salmeterol; Placebo to indacaterol and glycopyrronium (QVA149)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-03
    Completion
    2012-03
    Enrolment
    523

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Obstructive Pulmonary Disease (COPD)
    Interventionindacaterol and glycopyrronium (QVA149); Placebo to fluticasone/salmeterol; fluticasone/salmeterol; Placebo to indacaterol and glycopyrronium (QVA149)
    PhasePhase 3
    Registry statusCompleted

  • A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

    NCT01279057 · start 2010-12-27

    Registered record
    Registry ID
    NCT01279057
    Conditions
    Rhinitis, Allergic, Seasonal
    Interventions
    Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals); Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-12-27
    Completion
    2011-02-08
    Enrolment
    727

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Seasonal
    InterventionFluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals); Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/Long Acting Beta Agonist Combination Treatment for Asthma

    NCT01248975 · start 2010-12

    Registered record
    Registry ID
    NCT01248975
    Conditions
    Asthma
    Interventions
    FP/SAL 250/50mcg BID; GSK2190915 200mg QD (AM); GSK2190915 100mg QD (AM); Montelukast 10mg QD (PM); Placebo tablets (2) (AM); Placebo capsule (PM)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-12
    Completion
    2011-10
    Enrolment
    145

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionFP/SAL 250/50mcg BID; GSK2190915 200mg QD (AM); GSK2190915 100mg QD (AM); Montelukast 10mg QD (PM) +2 more
    PhasePhase 2
    Registry statusCompleted

  • Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on Fluticasone Furoate Nasal Spray in a Retail Pharmacy Setting

    NCT01337323 · start 2010-09

    Registered record
    Registry ID
    NCT01337323
    Conditions
    Rhinitis, Allergic, Seasonal; Seasonal Allergic Rhinitis
    Interventions
    Fluticasone furoate nasal spray
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2010-09
    Completion
    2011-09
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Seasonal; Seasonal Allergic Rhinitis
    InterventionFluticasone furoate nasal spray
    PhaseNot recorded
    Registry statusTerminated

  • Single Dose Pharmacokinetics of Intranasal Azelastine Delivered by a Fixed Combination With Fluticasone in Comparison to Azelastine Nasal Sprays

    NCT01190852 · start 2010-08

    Registered record
    Registry ID
    NCT01190852
    Conditions
    Allergic Rhinitis
    Interventions
    Azelastine, Fluticasone; Azelastine mono; Azelastine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-08
    Completion
    2010-10
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis
    InterventionAzelastine, Fluticasone; Azelastine mono; Azelastine
    PhasePhase 1
    Registry statusCompleted

  • BI 671800 ED in Steroid-naive Asthmatic Patients

    NCT01092143 · start 2010-03-18

    Registered record
    Registry ID
    NCT01092143
    Conditions
    Asthma
    Interventions
    BI 671800; Fluticasone propionate placebo; Fluticasone propionate; BI 671800 Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-03-18
    Completion
    2011-03-26
    Enrolment
    389

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionBI 671800; Fluticasone propionate placebo; Fluticasone propionate; BI 671800 Placebo
    PhasePhase 2
    Registry statusCompleted